Copper Hits Two-Week High

Source: Reuters (12/1/10)

"The dollar weakening is still supportive to the complex."

Copper rose to its highest in two weeks on Wednesday, buoyed by data out of top consumer China and a weaker dollar.

Three-month copper on the London Metal Exchange traded at $8,499/ton in rings, extending gains made on Tuesday, when it closed at $8,360. The metal used in power and construction earlier touched a session high of $8,537.75.

"The dollar weakening is still supportive to the complex," Standard Bank Analyst Leon Westgate said.

"The U.S. economic data was also pretty solid. . .the Chinese data was also pretty good."

Better-than-expected Chinese factory data in November, with the official Chinese Purchasing Managers' Index (PMI) rising to a seven-month high of 55.2, showed health in one of the world's largest economic engines, lifting sentiment. Data on Tuesday showed U.S. consumer confidence rose in November to its highest in five months and U.S. Midwest business activity grew faster than expected.

A looming deficit in the copper market is expected to push copper prices next year above the record high of $8,966 hit early November.

Bolstering this outlook, LME copper stocks have fallen steadily since February, last down 900 tons to 354,850 tons—their lowest since October 2009.

Dominant Position

Investors also kept close tabs on a dominant position controlling 50%–80% of cash warrants for copper, subject to LME lending guidance.

In U.S. economic news that could impact metals via currency movements, the Institute for Supply Management releases its November manufacturing PMI at 1500 GMT.

In other news, China's arrivals of copper scrap should be low in November and December as importers cut spot bookings in the past two months on high prices, after the inflow fell a fifth in October, traders said on Wednesday.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.

Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data
Source: Streetwise Reports (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.

Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug
Source: Streetwise Reports (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.

AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients
Source: Streetwise Reports (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.

NGL Energy Shares Rise 21% as It Seeks to Raise $2.05 Billion from Senior Secured Note Offering
Source: Streetwise Reports (01/21/2021)

Shares of NGL Energy Partners LP traded higher after the firm made a series of announcements over the past three days regarding an update on financial operations, a settlement with a customer in bankruptcy, a quarterly Class D unit distribution and a $2.05 billion senior secured debt offering.

Explorer Discovers New Gold Mineralization at Abitibi Gold Belt Property
Source: Streetwise Reports (01/21/2021)

iMetal Resources is setting out to see if the multi-million ounce gold resource next door continues onto its Gowganda West property in Ontario.

Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine
Source: Streetwise Reports (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.